

---

# Differential Diagnosis and Treatment Strategies for Biologic Complications and Failing Oral Implants: A Review of the Literature

Marco Esposito, DDS\*/Jan Hirsch, DDS, PhD\*\*/Ulf Lekholm, DDS, PhD\*\*\*/  
Peter Thomsen, MD, PhD\*\*\*\*

The aim of this article was to review the literature on differential diagnosis and treatment of biologic complications and failing implants. All types of publications, with the exception of abstracts, published in English up to December 1998, were included. A multi-layered search strategy was used. Controlled clinical trials (CCTs) were searched in the Cochrane Oral Health Group's Specialized Register of Trials. This database contains all CCTs identified in MEDLINE and EMBASE. PubMed was searched using various key words and the "related articles" feature. All identified publications were obtained and none were excluded. Infection, impaired healing, and overload are considered the major etiologic factors for the loss of oral implants. Only a few clinical and animal investigations were found that tested the validity of the proposed therapeutic approaches. The treatment of failing implants is still based mainly on empirical considerations, often derived from periodontal research, from data extrapolated from in vitro findings, or from anecdotal case reports performed on a trial-and-error basis. (INT J ORAL MAXILLOFAC IMPLANTS 1999;14:473-490)

**Key words:** complication, dental implant, evidence-based treatment, failing implants, guided bone regeneration, infection, peri-implantitis, therapy

---

**T**he literature analyzing failures of osseointegrated oral implants is rapidly increasing.<sup>1,2</sup> The attention of the scientific community is gradually shifting from descriptions of success rates to a detailed analysis of complications and failures affecting different patient groups and various implant systems. With such an approach, it might

be possible to further optimize success rates by developing new implants with improved properties and by performing adequate patient selection. However, the literature also points to an incomplete understanding of processes leading to implant loosening.

This review includes literature published in English up to December 1998. A multi-layered search strategy was adopted. Controlled clinical trials (CCTs) on osseointegrated oral implants were searched in the Cochrane Oral Health Group's Specialized Register of Trials. Such a database, which is continually being expanded, contains all identified randomized controlled clinical trials (RCTs) and CCTs regarding oral health (more than 5,000 references) found in 2 major electronic databases (MEDLINE and EMBASE).

The database also includes articles obtained from the Oral Health Group's program of manually searched journals. The following journals were manually searched: *Clinical Oral Implants Research*, *Journal of Oral Implantology*, *Oral*

---

\*Researcher, Institute of Anatomy and Cell Biology, Göteborg University, Göteborg, Sweden.

\*\*Professor, Department of Oral and Maxillofacial Surgery, Uppsala University Hospital, Uppsala, Sweden; and Department of Oral and Maxillofacial Surgery, Göteborg University, Göteborg, Sweden.

\*\*\*Professor, The Bränemark Clinic, Public Dental Health of Göteborg; and Faculty of Odontology, Göteborg University, Göteborg, Sweden.

\*\*\*\*Professor, Institute of Anatomy and Cell Biology, Göteborg University, Göteborg, Sweden.

**Reprint requests:** Dr Marco Esposito, Institute of Anatomy and Cell Biology, Göteborg University, P.O. Box 420, SE-405 30 Göteborg, Sweden. Fax: +46 (0) 31 7733308. E-mail: marco.esposito@anatcell.gu.se

*Implantology, Implant Dentistry, International Journal of Oral Implantology, and Implantologist.* In addition, PubMed was searched independently for any type of study pertinent to the topic using various key words and the "related articles" feature. Reference lists of previously published reviews and of all potential articles of interest were scrutinized for additional articles. A personal library based on a reference database (End-Note 3.0, Niles Software, Berkeley, CA) containing more than 2,800 journal articles, book chapters, conference proceedings, and dissertations related to oral implants was created, consulted, and continuously updated. All potentially interesting articles, including animal and in vitro studies, case reports, and reviews, were obtained and catalogued. No identified articles were excluded. Abstracts were not included.

Neither the role of hyperbaric oxygen therapy on irradiated patients, which has recently been extensively reviewed,<sup>2,3</sup> nor biomechanical complications/failures and major bone grafting procedures are discussed in this review. A critical evaluation of the techniques used for assessing the peri-implant tissue conditions can be found in Esposito et al.<sup>1</sup> For reviews regarding the maintenance of osseointegrated oral implants, the reader is referred elsewhere.<sup>4-6</sup> Reviews on the therapy of failing implants and complications have previously been presented.<sup>6-8</sup> The relationship of risk factors, such as smoking to the frequency of failures has been discussed extensively elsewhere.<sup>2,9,10</sup> No articles related to the role, if any, of risk factors in the treatment of failing implants were found.

To facilitate the establishment of a correct diagnosis and to implement the most effective treatment, the authors planned to follow an evidence-based decision-making strategy. Such an approach is used to help clinicians and researchers in making decisions based on the knowledge contained within the literature.<sup>11</sup> Decisions have to be made even in the absence of adequate information, and it is difficult to construct deductive reasoning when essential facts are unknown. The purpose of medical decision-making is to support clinicians in making good decisions despite uncertainty.<sup>12</sup> However, as the scientific literature regarding treatment of biologic complications and failing implants is still scarce, case reports as well as intuitions are critically discussed here if they are the only source of information available. Although one must be very cautious when inferring conclusions from clinical experience or intuitions, such considerations may be valuable, since they form hypotheses for future research. Unfortunately, the authors

soon realized that it was impossible to apply decision-making principles, since prevalence estimates of signs and symptoms, as well as success rates of a given therapy for failing implants, were almost completely absent in the literature.

Two additional comments ought to be made: (1) In general, studies reporting negative results are seldom published. Therefore, there is a high possibility that reviews are unwillingly biased toward positive results. (2) When there is inconclusive evidence, it is a common mistake to confuse "no evidence of effect" with "evidence of no effect."

The aim of the present article was to review the literature on the differential diagnosis and the treatment of biologic complications and failing implants.

### Definitions and Etiopathogenesis of Implant Failures

The present review is focused on biologic complications and failures of osseointegrated oral implants. Osseointegration has been described as the "direct anchorage of an implant by the formation of bony tissue around the implant without the growth of fibrous tissue at the bone-implant interface."<sup>13</sup> For more detailed definitions of osseointegration, success, and failure, the reader is referred elsewhere.<sup>1</sup>

A biologic failure can be defined as the inadequacy of the host to establish or to maintain osseointegration. The inability to establish osseointegration can be regarded as an early failure, whereas the inability to maintain the achieved osseointegration, under functional conditions, may be considered a late loss.<sup>1</sup>

From a therapeutic point of view, the distinction between failed implants, failing implants, and biologic complications is critical. Clinically, lack of osseointegration is generally characterized by implant mobility.<sup>1,14</sup> Therefore, in principle, a mobile implant is a failed implant. However, the failure process may be slow and gradual.<sup>14</sup> Therefore, an implant that is progressively losing its bone anchorage, but is still clinically stable can be defined as "failing." If properly recognized and treated, a "failing" implant might be saved. A biologic complication may indicate an increased risk for failure, which can be of temporary significance or amenable to treatment. To be more precise, a biologic complication can be defined as a soft tissue aberration without loss of the supporting bone. Decubitus ulcers of the mucoperiosteum covering a healing implant, peri-implant mucositis,<sup>15</sup> hyperplastic mucositis,<sup>7</sup> and some fistulae can be considered biologic complications.

Another term, often encountered in the North American literature, is “ailing” implant.<sup>16-21</sup> In general, an “ailing” implant has been defined as a clinically stable implant affected by bone loss with pocketing.<sup>17,19,21</sup> For these authors, the major difference between an “ailing” and a “failing” implant is the outcome of the therapy. In fact, if an “ailing” implant is resistant to therapy it becomes “failing.” In other words, the term “ailing” implies a somewhat more favorable prognosis than “failing.”<sup>17,21</sup> Other definitions of an ailing implant have also been given.<sup>16,19,20</sup> For instance, Krauser<sup>16</sup> considered an implant to be “ailing” when affected by soft tissue aberrations without loss of supporting bone. The latter definition seems preferable and will be used as a synonym for biologic complication in the present review.

In general, problems limited to the soft tissue compartment and not involving the supporting bone are thus defined as “biologic complications” (“ailing” implants). If the supporting bone is involved and the implant is still stable, the implant is “failing.” The implant is “failed” if mobile.<sup>22</sup> When testing the stability of an implant, the clinician must be able to discriminate between a mechanical complication, such as a mobile abutment, and a mobile implant (biologic failure). It is evident that it may not be always possible to clearly differentiate among established failures, “failing” implants and biologic complications (“ailing” implants).

Most likely, implant complications and failures have a multifactorial background.<sup>1,2,9,22-30</sup> Three major etiologic factors, which in some instances, may overlap, have been suggested: infection, impaired healing, and overload.

**Infection.** Complications, “failing” implants, and failures attributable to bacterial infection can occur at any time during implant treatment.<sup>1,25</sup> Infection can be induced by direct bacterial contamination of the implant surface at implant placement,<sup>31-33</sup> by bacterial contamination from neighboring infected dental structures,<sup>34</sup> and by plaque accumulating on the exposed surfaces of the biomaterial (peri-implant mucositis, hyperplastic mucositis, some fistulae originating from the soft tissue compartment after abutment connection, and peri-implantitis).<sup>23</sup>

In this context, the term “peri-implantitis” needs to be properly defined. In fact, peri-implantitis has been referred to as “inflammatory reactions with loss of supporting bone in the tissue surrounding a functioning implant.”<sup>15</sup> Since it is very likely that all late failures are mediated by an inflammatory process,<sup>29</sup> such a definition seems

too generic. The words “plaque-induced infection” could be included in the definition of peri-implantitis, in analogy with the term periodontitis, from which it has derived. Mombelli et al<sup>23</sup> regarded peri-implantitis as a site-specific infection yielding many features in common with chronic adult periodontitis. Tonetti described the condition as “an inflammatory, bacterial infection-driven destruction of the implant-supporting apparatus.”<sup>35</sup> An alternative definition could be the following: a site-specific, plaque-induced infection with progressive loss of the bone supporting a functioning implant.

The soft tissue complications around implants (peri-implant mucositis, hyperplastic mucositis, fistulation, and mucosal abscess) seem mainly to have an infectious etiology.<sup>29,36,37</sup> Bacteria can be found at the connection between the implant and the cover screw/abutment.<sup>38,39</sup> Fistulations<sup>40-47</sup> and hyperplastic mucositis<sup>42,48</sup> are often found in conjunction with loose prosthetic components. Fistula formations<sup>44</sup> and abscesses<sup>49</sup> can occasionally be seen in relation to dense food particles trapped in the peri-implant crevice. Hyperplastic mucositis seems to be more common under overdentures,<sup>50,51</sup> possibly as a result of a shift in the composition of the microflora,<sup>52</sup> but it has also been observed in relation to treatment with dilantin sodium, an anti-convulsive agent.<sup>53</sup>

**Impaired Healing.** Failures related to impaired healing are generally discovered in conjunction with the second operation for connecting the abutment in 2-stage systems (unpublished observations). The magnitude of the surgical trauma (ie, overheating, etc), micromotion, and some local as well as systemic characteristics of the host are believed to play a major role.<sup>2</sup>

**Overload.** The term “overload” is rather imprecise and may be somewhat misleading; nevertheless, it is widely used. In its most general meaning, failures related to “overload” include those situations in which the functional load applied to the implants exceeds the capacity of the bone to withstand it. An animal study has reproduced such a situation.<sup>27</sup> Also, failures that occur between abutment connection and delivery of the prosthesis, possibly caused by premature or unfavorable loading conditions or induced by the prosthetic procedures, may, in many instances, be considered to have an “overload” etiology (unpublished observations). Obviously, the term “overload” has to be considered in relation to a reduced “supporting” capacity of the bone surrounding an implant at a given time. The possible factors associated with the “overload” etiology have been extensively reviewed.<sup>2</sup> Yet unknown systemic or

local diseases and pharmacologic effects that alter bone metabolism and/or influence the bone remodeling capacity may be involved.

The goal of the treatment of complications and failing implants is to leave the patient with a functional restoration and acceptable esthetics. Therefore, arresting further loss of bone support and re-establishing a healthy peri-implant mucosal seal should be the goal of treatment. Attempts to eliminate osseous defects or to stimulate bone formation to regenerate lost supporting bone would be the ideal goal.<sup>54-56</sup>

### Differential Diagnosis of Biologic Complications/Failures

Patients can exhibit similar signs, symptoms, and results of diagnostic tests, though relative to different etiologies. Thus, the determination of the exact cause for a complication or failure may be difficult. Before attempting any treatment, a differential diagnosis should be established. A differential diagnosis consists of a cyclic process based on the patient anamnesis and physical examination. The steps behind this process may be summarized as follows: (1) generate alternative hypotheses, (2) gather data, (3) use the data to test the hypotheses, and (4) select a course of action.<sup>12</sup> However, a differential diagnosis is fundamental only if it will influence the therapeutic approach. If further information would not change the treatment decision, the diagnostic search becomes less relevant. The tools available for making a diagnosis and their reliability have been recently reviewed.<sup>1,8</sup>

Ideally, clinical, radiographic, microbiologic, and histologic information should be combined to obtain a comprehensive overview of the problems involved. However, such an approach is feasible only in experimental conditions, but not in the clinical situation, where the therapist usually has access only to clinical and radiographic information.

As previously mentioned, complications and failures can occur at different stages of the implant treatment. For simplicity, a distinction between problems occurring before prosthesis placement and after prosthesis placement has been made.

**Before Prosthesis Placement.** Problems can be discovered at different time points (before, during, or after abutment connection), and the diagnostic decision-making process has to be adapted accordingly. In case of wound dehiscence, early infection signs such as swelling, fistulae, or persisting pain occurring during the submerged period in the case of a 2-stage procedure, a clinical investigation with repeated intraoral radiographs may be useful in

determining whether the problem is confined to the soft tissue compartment (eg, complications resulting from residual suture material,<sup>40,48,57,58</sup> poorly seated cover screws,<sup>40,59</sup> wound dehiscence caused by premature wearing of the denture or inadequate relief of the denture on protruding implants,<sup>40,57,58,60</sup> etc) or if it concerns the supporting bone. In case of persisting doubts, exploration surgery may be indicated to directly visualize the area and test the implant for stability. Radiographs should be inspected with regard to the presence of a radiolucent line surrounding the implant and for localized bone rarefaction. The relationship between the implant and adjacent structures (neighboring teeth, inferior alveolar nerve, etc) should be investigated.

Occasionally, peri-implant apical radiolucencies have been reported,<sup>61-66</sup> with a prevalence of 0.26%.<sup>63</sup> These lesions are often found around long implants placed in dense bone. Radiographically, the coronal portion of the implant is supported by "normal" bone in intimate contact with a stable implant. These lesions may be completely asymptomatic or discovered in relation to tenderness or persistent pain and/or swelling and fistulation. A distinction between inactive (noninfected) and infected lesions has been suggested based on radiographic and clinical criteria.<sup>63</sup> The etiology is unknown but seems to be multifactorial. Inactive lesions are likely to be apical scars resulting either from a residual bone cavity created by placing shorter implants than the drilled implant site<sup>63</sup> or from a heat-induced aseptic bone necrosis.<sup>61,63,65</sup> Bacterial contamination of the implant surface has been considered in the presence of fistulation or abscess formation.<sup>61-64</sup>

At the time of abutment connection, implants should be tested for mobility and baseline control radiographs taken. Mobility is the cardinal sign of implant failure.<sup>1</sup> Stable implants with radiographic signs of bone loss should be viewed with suspicion, since an infection may be involved (unpublished data).

After abutment connection, the patient may perceive a painful sensation when a connecting screw is tightened or an implant is loaded. Usually, implants with such symptomatology are found to be mobile (unpublished data). Signs of infection or mucosal aberrations may also be present and, in the case of a stable implant, a differential diagnosis between a complication and a "failing" implant should be made with the help of intraoral radiographs. Radiographic examination should assist in solving the diagnostic doubt discriminating between suspicious bone loss, an improperly seated abutment, or no apparent anomaly.

**After Prosthesis Placement.** After prosthesis placement, the patient should be enrolled in a custom-designed maintenance program. Soft tissue conditions, prosthesis stability, and occlusion should always be inspected and, at regular follow-up intervals, intraoral radiographs should be taken. In the presence of soft tissue aberrations, fistulation, swelling, pus, mobility of restorations, painful sensation when chewing, suspected peri-implant radiolucency, or excessive marginal bone loss, the clinician must identify the possible etiology of the problem and take appropriate measures. Intraoral radiographs may be very useful in the diagnostic process. The presence of gaps between implant components or an excessive marginal bone loss can be seen. A radiolucent line surrounding a part of an implant or the entire implant or localized bone rarefaction can occasionally be observed. In case of excessive marginal bone loss, peri-implant radiolucency, and bone refraction, the prosthesis must be removed to document implant stability. In some instances, fractured implants can display a radiographic image of a bony crater similar to that observed at implants affected by peri-implantitis.<sup>67</sup> After all diagnostic information is gathered, a differential diagnosis between a failed, "failing," or "ailing" implant can be attempted. It should also be noted that "excessive" marginal bone loss seen during the first year of loading does not automatically result in soft tissue problems or progressive bone loss over time.<sup>68</sup> A retrospective study including 107 Brånemark implants that had exhibited bone loss up to the second thread after 1 year in function and were followed for up to 5 years showed that only 3 implants failed. In particular, 2 of the 4 implants that manifested signs of infection ultimately failed.<sup>68</sup>

### Evaluation of the Published Literature

Despite the fact that only a few clinical studies have been published on the treatment of failing oral implants,<sup>67,69-71</sup> there are several publications that give suggestions and offer guidelines on how "failing" implants should be treated.<sup>6-8,17,19,54,70,72-85</sup> Animal studies, case reports, and in vitro investigations on the topic have been reviewed as well. To ensure a comprehensive analysis of the literature, the authors decided to group articles and book chapters dealing with the topic in preventive measures and therapeutic measures (Table 1).

**Preventive Measures.** *Preventive Pharmacologic Therapy.* In a prospective RCT, prophylactic antibiotics administered prior to implant placement were found to decrease early failure rates by about 2 to

3 times, even though postoperative antibiotics were administered in 96% of the subjects.<sup>86</sup> Another retrospective controlled study did not show a statistical difference in infection rates in a group of patients who received antibiotic prophylaxis when compared to subjects without any antibiotic coverage.<sup>87</sup> The authors concluded that antibiotics administered for routine dental implant surgery offered no advantages for the patient. This apparent contradiction between the 2 trials may be partly explained by differences in the designs of the 2 investigations. In fact, the latter study<sup>87</sup> was retrospective, not randomized, included 2 groups of patients treated in different time periods, and did not report data on early losses. It is therefore possible that the trial was not able to show the effect of antibiotic prophylaxis that might have been present.

Rinsing with chlorhexidine has been found to reduce infective complications during the submerged period (RCT).<sup>88</sup> However, when preoperative antibiotics were given, the rate of infectious complications was essentially the same whether or not adjunctive antiseptic therapy was administered. In another RCT, adjunctive chlorhexidine rinsing twice daily for 30 seconds was shown to be effective in reducing plaque accumulation and superficial bleeding around oral implants.<sup>89</sup> Another RCT by the same group showed that subgingival chlorhexidine irrigation (0.06% once daily) resulted in a statistically significant reduction of plaque, but not superficial bleeding, when compared to 0.12% chlorhexidine rinsing.<sup>90</sup> Both therapies were effective in reducing superficial bleeding from baseline. Another RCT investigation failed to disclose any advantage of 8 weeks of subgingival irrigation with 0.12% chlorhexidine over saline-irrigated controls or no treatment at all in maintenance patients.<sup>91</sup>

The use of a chlorhexidine gel has been proposed as an adjunct to mechanical plaque control.<sup>82</sup> A 35% phosphoric etching gel was compared to standard supportive mechanical therapy in a split-mouth RCT.<sup>92</sup> The maintenance procedure was repeated monthly over a 5-month period. Both treatment modalities resulted in statistically significant improvement of Gingival Index and probing depth from baseline. The authors observed that an advantage with the chemical agent was that the implant surface was not instrumented, thus minimizing risk of damage.<sup>92</sup>

The use of anti-inflammatory drugs has also been suggested to prevent marginal bone loss. A nonsteroidal anti-inflammatory drug (flurbiprofen) administered for 3 months was found to signifi-

cantly reduce bone loss around implants in humans (RCT).<sup>93</sup> However, multicenter trials in larger groups of patients are needed before a new indication for a drug can be approved.

*Preventive Debridement.* It has been suggested that a preventive program for osseointegrated oral implants should include oral hygiene instructions and professional debridement every 3 months in partially edentulous patients.<sup>72,73</sup> This assumption was based on a histologic and microbiologic study, which showed healthy peri-implant mucosa when

mechanical debridement was performed every third month.<sup>94</sup> The authors also suggested that edentulous patients may require less frequent recalls.<sup>72</sup> Such a preventive strategy seems to be strongly influenced by microbiologic findings, which have indicated the possibility of transmitting periodontal pathogens from teeth to implant crevices.<sup>95-99</sup> However, in a meta-analysis, the finding of lower failure rates of Brånemark implants in partially edentulous patients (26 trials), when compared to totally edentulous patients

**Table 1 Summary of Clinical Studies in Relation to Proposed Prevention or Treatment Modalities for Biologic Complications and Failing Implants\***

Proposed treatment modality	Comments
Preventive measures	
Pharmaceutical therapy	
Prophylactic antibiotics <sup>86,87</sup>	Reduces early failures
Postoperative antibiotics <sup>86</sup>	Less effective than prophylactic antibiotics
Peri-operative chlorhexidine rinsing <sup>88</sup>	Reduces complications, if prophylactic antibiotics are not administered
Chlorhexidine rinsing <sup>89,90</sup>	Reduces superficial bleeding
Chlorhexidine gel application	Not investigated
Chlorhexidine subgingival irrigation <sup>90,91</sup>	Contradictory results
Monthly phosphoric acid gel application <sup>92</sup>	Reduces superficial bleeding and probing depths
Nonsteroidal anti-inflammatory drug (flurbiprofen) <sup>93</sup>	Reduces marginal bone loss (not yet indicated)
Mechanical debridement	
Monthly professional debridement <sup>92</sup>	Reduces superficial bleeding and probing depths
Surgery	
Attached mucosa extension procedure prior to implant placement	Not investigated
Attached mucosa extension procedure after implant placement	Not investigated; see text for more information
Pocket depth reduction at implant placement <sup>116</sup>	Reduces pocket depths, but increases perforations
Selected mucosal surgery to facilitate oral hygiene maneuvers	Not investigated
Implant surface modification (implantoplasty)	Not investigated
Therapeutic measures	
Mechanical debridement	Not investigated
Pharmaceutical therapy	
Chlorhexidine subgingival irrigation	Not investigated; possibly ineffective <sup>151</sup>
Local antibiotic therapy (tetracycline fibers) <sup>152</sup>	Inconclusive results
Systemic antibiotic therapy (various regimens)	Not investigated
Systemic ornidazole + chlorhexidine subgingival irrigation <sup>67</sup>	Effective
Anti-inflammatory drugs	Not investigated
Occlusal therapy (healing prolongation, prosthesis removal)	Not investigated
Surgical therapy for biologic complications	
For early soft tissue perforation during the submerged phase	Not investigated
For hyperplastic mucositis	Not investigated
Fistula originating from soft tissues	Not investigated
Surgical therapy for failing implants	
Open flap debridement	Not investigated
Bone resective procedures	Not investigated
Bone regenerative procedures <sup>7,19,49,69-71,74,111,115,167,177,178,181,196,197,209</sup>	Unpredictable; bone fill can be obtained; no firm evidence of reosseointegration; see text
Implant surface "detoxification" procedures (various types)	Not investigated; rarely proven to be more effective than saline in vitro; see text for more information
"Implantoapicectomy"	Not investigated

\*As presented in the literature up to December 1998.

(29 trials), does not seem to support this view.<sup>1</sup> In addition, professional debridement at 3-month intervals may not be necessary for all implant patients but only those who may be particularly susceptible to peri-implant infections.

Mechanical debridement using carbon fiber curettes and rubber cup was found to be effective in reducing bleeding sites and probing depth.<sup>92</sup>

*Preventive Surgery.* Preventive surgical procedures, aimed at increasing the resistance of peri-implant supporting tissues versus an external bacterial challenge, have also been recommended.<sup>17</sup> The following procedures have been proposed: increasing the thickness of the attached mucosa surrounding the implants, reducing pocket depths,<sup>98,100,101</sup> or changing an unfavorable peri-implant tissue anatomy to facilitate oral hygiene.<sup>17</sup>

Procedures aimed at increasing the volume of attached mucosa (free soft tissue grafts, pedicle soft tissue grafts, and surgical extension of the vestibulum) have been recommended in areas of movable mucosa.<sup>75,77,102-111</sup> Some authors believe that keratinized tissue should be created prior to implant placement.<sup>112,113</sup> Such procedures have been advocated in the belief that increased failure rates occur in areas deficient in attached keratinized mucosal tissues.<sup>77,109,113-117</sup> However, such arguments have not been supported by any scientific evidence. In fact, at present, there are no scientifically based clinical data or indications that implants penetrating movable mucosa are at a higher risk for failure.<sup>95,116,118-129</sup> In addition, patients treated with palatal mucosal grafts prior to implant placement have reported severe postoperative pain.<sup>106</sup> Therefore, preventive surgery should be confined to few indications, for instance, when an altered morphology of the peri-implant tissues would facilitate oral hygiene.<sup>17,42,57,73,128,130-132</sup>

At implant placement, a flap technique to reduce the thickness of the mucosa, to prevent the formation of deep pockets, and to preserve the attached mucosa has been proposed.<sup>116</sup> Although shallow pockets were consistently recorded in the test group, no obvious advantage in terms of success rates was noticed (CCT). Regrettably, the technique resulted in an increased number of mucosal perforations during healing.<sup>116</sup>

Flap thinning and placement of a surgical pack at abutment connection has been suggested to prevent deep pockets and peri-implantitis.<sup>99-101</sup> No scientific evidence has indicated whether this procedure is necessary.

Another issue sometimes discussed is the role of implant surface modification (implantoplasty<sup>54</sup>). This procedure is aimed at removing macro- and

microscopic structures from the implant/abutment surface that may favor plaque accumulation in the supracrestal portion of the bone defect.<sup>17,19,54,74-76,78,84</sup> The surface of the implant is smoothed with rotary instruments. Such a procedure should be performed under profuse irrigation before osseous surgery.<sup>54</sup> While intuitively sound, no scientific data have proven the validity of this measure. However, the operator should avoid excessively weakening the implant structure, since the chance of mechanical failure may be increased.

**Therapeutic Measures.** The following treatments have been suggested: mechanical debridement, pharmacologic therapy, occlusal therapy, and surgical therapy. Obviously, these different approaches may be combined to increase the chances of saving a "failing" implant. In case of bacterial infection, it has been suggested to start treatment by controlling the acute inflammatory phase via mechanical and chemical therapy, then following with the surgical phase, if necessary.<sup>17,54,75,83,84,133</sup>

*Mechanical Debridement.* Local debridement of hyperplastic peri-implant tissues using hand or ultrasonic plastic instruments has been suggested.<sup>17,54,69,75,77,84</sup> The recommendation to avoid metallic or hard instruments when touching the abutment/implant surface, so as to minimize surface damages and roughening, which can favor plaque adhesion, has been based on several in vitro investigations.<sup>134-147</sup> However, it should be noted that implant surfaces are abraded by toothbrush bristles as well<sup>134,148</sup> and that roughening of the surface by different maintenance methods has not yet been shown to increase the amount of mineralized deposits on abutments or their adherence to implant surfaces.<sup>149</sup>

*Pharmacologic Therapy.* In case of suspected infectious complications and peri-implantitis, adjunctive subgingival irrigation of the pocket with 0.12% to 0.2% chlorhexidine 2 to 3 times per day for 10 days to 3 weeks has been suggested as an efficient local disinfectant.<sup>67,76,77,82,84,85,150</sup> Chlorhexidine is believed to be the antimicrobial agent of choice.<sup>77,84</sup> However, its bactericidal effect in vivo at low concentrations (0.12% to 0.2%), coupled with crevicular fluid dilution and the apparent protective function of serum, may render chlorhexidine weakly bactericidal or even ineffective.<sup>151</sup> No scientific data have yet validated the effectiveness of chlorhexidine when used subgingivally around implants.

Local application of tetracycline fibers has also been proposed as an effective adjunctive treatment for failing implants.<sup>76,77,83,152</sup> Preliminary findings

from a CCT on the use of tetracycline fibers were inconclusive.<sup>152</sup> Only implants affected by hyperplastic mucositis, without marginal bone loss, were treated. The authors reported that no differences in probing depths, attachment levels, or probing bone levels were found when compared to scaled control implants. However, no data relative to any of these measurements were provided. It was speculated that the hyperplastic mucositis was markedly reduced around test implants. It would have been more valuable to treat implants that exhibited marginal bone loss. In addition, as discussed by the authors, control implants should have been treated with the "standard procedure," ie, abutment removal and sterilization. Properly designed clinical trials are therefore needed to evaluate the effectiveness of tetracycline fibers around failing implants.

If systemic antibiotic therapy is considered, it has been suggested that it be guided by bacterial culturing and sensitivity tests.<sup>5,17,22,54,73,76,77,153</sup> However, it is unknown whether the results of such diagnostic tests would actually influence the course of the therapy. Bacteria associated with failing implants have been found to be sensitive to the following antibiotics: penicillin G, amoxicillin, combination of amoxicillin and metronidazole, and amoxicillin-clavulanate, respectively.<sup>154</sup> Tetracycline and clindamycin were less effective.<sup>154</sup> Metronidazole and erythromycin were found to be ineffective at the tested concentrations.<sup>154</sup> However, the reader should also be aware that the concentrations used are valid only for suspended microorganisms. Bacteria around implants may form biofilms to protect themselves from the host.<sup>155-158</sup> Dental plaque is a typical example of biofilm. Although "biomaterial-centered infections" for implants placed in the maxillofacial region are rarely associated with conspicuous biofilms,<sup>159</sup> such deposits have been shown to protect the embedded bacteria from antibiotics in vitro.<sup>160-163</sup>

In case of suppurative peri-implant infection, the use of specific systemic antibiotics against anaerobic microorganisms is generally recommended.<sup>67,75</sup> In particular, it has been proposed that the administration of a combination of antibiotics (amoxicillin and metronidazole) be employed for 10 days.<sup>82,84</sup> This protocol is derived directly from the treatment of refractory periodontitis and is specifically targeted against *Actinobacillus actinomycetemcomitans*.<sup>164</sup> In an animal investigation, 3 weeks of combined amoxicillin and metronidazole administration in conjunction with open flap debridement and cleaning of implant surfaces resulted in resolution of the

peri-implantitis lesion and significant recession of the marginal peri-implant mucosa.<sup>165</sup> Controlled clinical studies validating the use of this antibiotic combination in patients with failing implants are lacking. Presently, systemic ornidazole (1000 mg for 10 days) together with chlorhexidine subgingival irrigation is the only antimicrobial therapy clinically tested in 9 patients for the treatment of failing implants.<sup>67</sup> The patients were monitored for 1 year and the therapy appeared to be successful in 8 patients.

The possibility of using nonsteroidal anti-inflammatory drugs for inhibiting peri-implant bone loss in cases of peri-implantitis has been proposed.<sup>72,166</sup> Even though preliminary animal results seem to be promising,<sup>166</sup> such therapy may not be indicated for the treatment of an acute phase.

*Occlusal Therapy.* When centric or lateral premature contacts or interference have been detected, occlusal adjustment has been recommended.<sup>17,54,69,70,75,77,133,167</sup> The fit of the prosthesis and the abutment should be evaluated.<sup>17,54</sup> When parafunctional activity is suspected, night-guard therapy has been suggested.<sup>77</sup> It has also been reported that if overload etiology is suspected, the clinician should remove the prosthesis with the hope of improving the situation.<sup>77</sup> Although such indications seem reasonable, they have not been confirmed by scientific evidence.

*Surgical Therapy.* Surgical procedures for the treatment of complications and "failing" implants have been advocated by several authors,<sup>78,82</sup> particularly after unsuccessful antimicrobial treatment and progressive marginal bone loss.<sup>82</sup>

Early perforations of the mucoperiosteum covering a submerged implant, often caused by decubital ulcers related to inadequate relief of the denture on the implant site,<sup>40,42,57,58,73,103</sup> can be treated with excision of the bordering mucosa, full-flap coverage of the perforation, and adequate relief of the denture.<sup>42,57,73,103</sup> For some implant systems, it is also possible to replace a standard cover screw with a smaller one. Hyperplastic mucositis refractory to increased oral hygiene procedures,<sup>42,73,168,169</sup> in the absence of other treatable conditions (ie, loose implant components that can be tightened after local cleaning and sterilization of the abutment<sup>103</sup>), is usually treated with gingivectomy procedures.<sup>51,53,57,103,104,170,171</sup> Chronic fistulae originating from infected soft tissues entrapped at the abutment junction level have been treated by removing the abutment and interposed granulation tissue, cleaning the implant head, sterilizing the abutment, fitting a new silicon ring (when present), surgically excising the epithe-



lialized sinus tract (not always necessary), and properly reseating the abutment.<sup>42,44,46,48,57,73,84,103</sup>

Surgical revision of failing implants is aimed mainly at cleaning the abutment/implant surfaces of bacteria (open flap debridement). Effective cleaning of the implant surface represents an important issue in the treatment of failing implants. In fact, cleaning rough implant surfaces is very difficult<sup>172</sup> since bacteria are protected in microirregularities or undercuts of the surface.<sup>173</sup> For this reason it seems wise to carry out any surgical intervention under antibiotic coverage to maximize the antibacterial effect.<sup>69,75,82</sup>

There is unanimous consensus that bacteria should be eliminated from the surfaces of failing implants. Further, there is a belief that if endotoxins or other contaminants are left, there cannot be biologic repair or reosseointegration.<sup>19,20,62,79-81,112</sup> It has been suggested that "detoxification" procedures should be performed only in areas where regenerative procedure techniques are contemplated.<sup>76</sup> This issue is controversial, lacking any in vivo evidence on the influence of different decontamination procedures on healing.<sup>79,83,174</sup> Results from in vitro studies<sup>151,175,176</sup> should be confirmed by in vivo findings, since direct extrapolations to the complex sequences of biologic events occurring at the implant interface in the clinical situation may be hazardous.

*"Detoxification" Procedures.* Various mechanical and chemical techniques have been proposed for cleaning "infected" implant surfaces. Low-speed rotary instruments can be used for removing the plasma-sprayed layer from rough surfaces.<sup>82</sup> Additional application of chlorhexidine gel for 5 minutes on the mechanically cleaned implant surface has been recommended to provide topical disinfection.<sup>82</sup> Other authors have used chlorhexidine rinsing.<sup>177,178</sup> However, in vitro investigations have shown that 0.12% chlorhexidine burnished with a cotton pellet for 1 minute did not remove more bacterial toxins from different implant surfaces than saline (machined, grit-blasted, hydroxyapatite- (HA) coated, or plasma-sprayed).<sup>172,179,180</sup> It has been suggested that "infected" surfaces of HA-coated implants should be cleaned with citric acid (pH 1) for 30 seconds to 1 minute,<sup>19,61,74,76,80,84,112,133,172,176,179-181</sup> although one in vitro study was unable to show any statistical difference with saline-burnished controls.<sup>78</sup> In another in vitro investigation,<sup>182</sup> it was concluded that citric acid "may be beneficial" for treating "infected" HA-coated implant surfaces. Indeed, the longer the surface was burnished with a cotton pellet independently from the chemical agents

tested, the more the thickness of the HA coating decreased. Thus, an alternative interpretation of these studies<sup>180,182</sup> may have been that no difference could be observed between a citric acid or a saline-burnished HA surface. A statistical difference in endotoxins removed from HA-coated surfaces in favor of citric acid was indeed shown in 2 in vitro investigations.<sup>172,179</sup> In a later study, it was concluded that cleaning the surfaces of failed implants of organic debris with citric acid for 30 seconds gave the best results.<sup>183</sup> However, no saline-cleaned controls were included.

Other authors used a Chloramine-T solution for disinfecting implant surfaces.<sup>69,70</sup> Results from an in vitro study did not show any advantage of this chemical compared to a saline solution.<sup>180</sup> The use of tetracycline has also been suggested,<sup>19,61,111,112,167,181</sup> despite being significantly less effective<sup>180</sup> or as effective as saline<sup>179</sup> in removing bacterial endotoxins. Burnished hydrogen peroxide has not been found to be superior to saline in removing bacterial endotoxins in vitro.<sup>179</sup>

It has been proposed that an "altered" HA coating be removed<sup>19,76,78,112</sup> or that titanium plasma-sprayed surfaces be cleaned with ultrasonic or air-powder abrasives.<sup>69,70,75,82</sup> Sonic scalers with plastic tips were found, in vitro, to be as effective<sup>180</sup> or more effective<sup>179</sup> than burnished-saline controls in removing endotoxins from implant surfaces. In vitro studies have shown that air-powered abrasives are able to clean a rough implant surface of bacteria,<sup>173</sup> bacterial toxins,<sup>172,180</sup> and organic materials.<sup>183</sup> However, it is not known whether air-powered abrasives can effectively clean narrow infrabony defects, as the contact profile angle may be too acute to deliver an effective spray to the implant surface.<sup>76</sup> In addition, as observed by Zablotsky,<sup>76</sup> such an acute angle of the air-powered abrasive instrument may induce emboli in the bone marrow spaces. Indeed, several authors<sup>75,76,78,82,112,133,184</sup> have advised against the risk of embolism induced by pressurized air when using air-powered abrasives. Despite the fact that only minor complications have been reported until now, following the use of air-powered abrasives,<sup>184,185</sup> the reader should be aware that the use of air-driven handpieces at implant placement has been directly related to the death of several patients.<sup>186,187</sup>

Preliminary results from an in vitro study<sup>188</sup> have shown that photosensitization and soft lasers can eliminate bacteria from different implant surfaces (ie, machined, sandblasted/acid-etched, flame-sprayed, and HA-coated) in 1 minute. However, no information was provided on temperature

changes induced by the laser. It is known from another *in vitro* study<sup>189</sup> that a CO<sub>2</sub> laser used for cleaning an implant surface induced a temperature of about 49°C at the interface. A temperature of 50°C for 1 minute was found to induce bone resorption, beginning 3 weeks after the heating episode, at titanium/bone interfaces in rabbits.<sup>190</sup> Obviously, the temperature at the implant surface varies according to several parameters (application time, power setting, continuous or pulsed mode, etc), and temperatures below 47°C can be obtained.<sup>191</sup> Laser treatment in dry conditions has not reduced the amount of organic contaminants on failed implants. In wet conditions, however, the amount of organic material was reduced to some extent, and burning and carbonization did not occur.<sup>183</sup> Another *in vitro* investigation showed that a neodymium-yttrium-aluminum-garnet laser used in dry conditions resulted in the melting of both HA and titanium plasma-sprayed coated surfaces, even at the lowest power setting. In addition, it did not sterilize the implant surface.<sup>192</sup> For an overview on the use of lasers in oral implantology the reader is referred elsewhere.<sup>193</sup>

*Resective and Regenerative Procedures.* Once the primary goal of surgical intervention (ie, a bacteria-free implant surface) has been achieved, it may be necessary to correct the anatomic conditions to improve plaque control and eliminate the favorable environment for anaerobic bacteria (ie, deep pockets). This may be accomplished either with resective procedures (bone resection and apically repositioned flaps) or with regenerative procedures (guided bone regeneration [GBR], autologous, or allogenic bone grafts). The decision-making process regarding the use of resective or regenerative procedures may be influenced by the degree and/or morphology of the peri-implant tissue destruction. If the amount of lost supporting bone is minimal, a resective approach may be preferable.<sup>75,78</sup> If a major portion of the supporting bone has been resorbed, forming a craterlike defect with remaining wall structures, a regenerative technique has been recommended.<sup>75,78</sup> Finally, if the destruction has reached the vents of a hollow-cylinder implant, or the remaining supporting bone is judged to be insufficient to withstand the usual loading conditions, the implant should be removed.<sup>54,75,81,133,194</sup>

After a flap is apically repositioned, it has been suggested that a surgical pack be used to secure the position of the flap.<sup>82</sup> No studies have been published that substantiated such a procedure.

Several animal studies and case reports have investigated the possibility of regenerating new sup-

porting bone around “failing” implants using barriers (GBR). For a review on the use of barriers with respect to oral implants the reader is referred elsewhere.<sup>195</sup> Partial bone fill around failing implants using GBR alone<sup>49,70,177,178,196</sup> or in combination with autogenous bone grafts<sup>7</sup> or various types of allografts/alloplastic grafts<sup>71,74,111,167,181,197</sup> have been reported. Despite different antibiotic regimens, barriers usually required premature removal because of infections.<sup>7,70,71,73,111,167,177,178,196,197</sup> It has been shown that premature barrier exposure and removal is generally associated with poor clinical outcomes.<sup>198</sup> Although some case reports have displayed a pronounced radiographic bone fill,<sup>167,196</sup> such results should be viewed with caution, since unsuccessful reports can be found as well.<sup>46,70,84,199</sup>

Animal studies have produced contradictory results regarding GBR, ranging from no “reosseointegration,”<sup>200,201</sup> to minimal “reosseointegration,”<sup>202-204</sup> to a clinically significant<sup>205</sup> “reosseointegration” and from no regeneration<sup>200,201</sup> to consistent bone regeneration<sup>202,203,205,206</sup> around various types of implants. Barriers were placed both in a completely submerged fashion<sup>200,202,204-206</sup> or adapted to a permucosal abutment.<sup>200-202</sup> Such differences in bone regeneration among different studies can be explained partly by anatomic variations of the bony defects and by barrier infections and exposures. In the studies by Grunder et al<sup>200,201</sup> mainly horizontal bony defects, which have lower potential for bone regeneration than circumferential infrabony defects,<sup>205,206</sup> were treated. Premature barrier exposures were common in those studies associated with poorer results,<sup>200,202</sup> with one exception.<sup>204</sup> The role of surface cleanliness for reosseointegration remains unclear, though the detergent (1% delmopinol HCl) used in one investigation<sup>204</sup> may contribute to the lack of reosseointegration. The combination of GBR and resorbable HA or freeze-dried bone resulted in a statistically higher percentage of reosseointegration when compared to GBR alone.<sup>205</sup>

An animal investigation has shown that recombinant human bone morphogenetic protein-2 has the potential to promote bone formation and reosseointegration in advanced peri-implantitis bony defects, although the amount of bone-to-implant contact in the reosseointegrated portion of bone was significantly lower than bone contact within the resident bone.<sup>207</sup>

It has been suggested that microbial leakage at the abutment-implant junction might influence the outcome of GBR.<sup>202,208</sup> In addition to sterilization of the abutment,<sup>57</sup> disinfection of the internal part of the implant has been advocated,<sup>208</sup> but its effec-

tiveness has not been proven. To improve the likelihood of bone regeneration, it has been recommended that the area be isolated from the oral cavity with a full-flap coverage of the barrier.<sup>54</sup>

Based on these clinical and experimental findings it may be concluded that GBR applied to failing implants does not yet provide predictable results. This procedure is technically demanding and should be considered as still being clinically tested.<sup>83</sup>

Anecdotal case reports describing the use of demineralized or autogenous bone grafts<sup>69,115,197</sup> and HA particles<sup>19,115,197,209</sup> around peri-implant defects have been presented, though results could not be objectively assessed or were failures.<sup>197</sup> No minimum follow-up or histologies are available to support these methodologies.<sup>174</sup> Haanæs<sup>153</sup> has strongly advised against using HA or allogenic freeze-dried bone to fill bone pockets around infected implant sites, warning of the potential consequences for the patient. In fact, biomaterial-centered infections may bear catastrophic consequences for the patient,<sup>153</sup> such as acute localized suppurative osteomyelitis.<sup>64</sup> Biomaterial-centered infections are extremely resistant to antibiotics<sup>2,61</sup> and combined antibiotic/surgical therapy.<sup>64</sup> Therefore, whenever a clinician feels uncertain with regard to the possibility of eliminating bacteria in an area of difficult access (ie, vents of hollow implants, rough coatings, etc) the solution of choice is implant removal.<sup>75,108,133,194</sup>

*Mobile Implants.* In case of frank mobility (ie, a soft tissue capsule surrounds the implant) the implant should be immediately removed, since progressive destruction of the surrounding tissue may occur.<sup>19,21,73,82,103,108,112,210,211</sup> All of the soft tissue capsule should be carefully curetted from the "socket" and the implant site should be completely covered with a mucoperiosteal flap to optimize the likelihood of bone regeneration.<sup>40,42,57,103,210</sup> If the removed implant is critical for prosthetic rehabilitation, it has been suggested that it can be immediately replaced with a wider implant and loaded after an appropriate healing period,<sup>57,212</sup> when an infectious etiology is not suspected.

Also, failing implants in which the spread of the infection has reached the vent of a hollow portion or are resistant to aggressive and combined antibacterial therapies, though still stable, should probably be immediately removed to circumvent major infectious complications, such as osteitis or osteomyelitis<sup>82,211</sup> or, especially in immunocompromised patients, severe life-threatening infections, such as descending necrotizing mediastinitis.<sup>213</sup> To achieve this, specially designed trephine burs can be used.<sup>82,214,215</sup> Particularly in situations

where long mandibular implants engage both cortical plates, the removal procedure should be planned carefully and accomplished under generous irrigation, since a case of fatigue fracture of the mandible has been described.<sup>82</sup> Osteomyelitis is another complication that has occurred after explantation with a trephine bur (unpublished data). Once the implant has been removed, the "socket" should be carefully curetted and closed via a flap procedure.<sup>40,42,57,103,210</sup> If the retrieved implant has been critical in the final prosthetic rehabilitation, it may be replaced after an appropriate healing period.<sup>61</sup>

It is generally believed that mobile (failed) implants will not reintegrate. However, as in orthopedic fracture surgery, the problem of delayed or nonunion of fractures is addressed by restarting the regenerative system by inducing a new bone injury.<sup>216</sup> There are a few case reports<sup>217,218</sup> and experimental investigations<sup>219,220</sup> indicating that a positive outcome may be achieved in some well-defined situations. Albeit speculative, a prolonged healing (for early failures) or a timely temporary reduction of the loading (for late failures) might prove beneficial in the presence of rotational mobility without bacterial infection and/or epithelial downgrowth/encapsulation.

*Apical Peri-implant Lesions.* The treatment strategy for implants with periapical lesions depends on the etiology. Stable asymptomatic inactive forms should be radiographically monitored. It has been recommended that infected lesions around stable implants be treated aggressively with combined antibiotic and surgical therapy.<sup>61-63</sup> Resection of infected implant apices may be considered in relation to the difficulties of having adequate access to clean the entire implant surface.<sup>62,63</sup> An extraoral surgical approach may be indicated in some situations.<sup>62</sup> The suggested additional use of bone autografts and/or freeze-dried bone allografts and barriers<sup>61,63</sup> does not seem to be justified.

## Conclusions

The treatment strategy for complications and failing implants is influenced by the identification of the possible etiologic factor(s). When a diagnosis is established and possible etiologic factor(s) identified (superficial infection, denture-induced mucosal perforation, deep infection involving supporting bone, etc), the causative agent should be eliminated and treatment attempted as soon as possible. Therefore, patients should be advised to report immediately any adverse symptoms such as pain, sensitivity on pressure, swelling, pus, mobil-

ity of the implant components, etc. In particular, the therapy of infected failing implants should be immediate, aggressive, and combined (prolonged systemic or local antibiotics and surgical debridement).<sup>84</sup> Antibiotic administration alone is unlikely to be successful because of the difficulties in eradicating bacterial colonies from surfaces of biomaterials.<sup>2,66,160-163</sup> If no improvement occurs, removal of the implant is indicated.

As summarized in Table 1, few clinical controlled studies and several case reports have been published on the treatment of biologic complications or failures. Therefore, it might be concluded that the treatment of biologic complications and failing implants lacks systematic scientific validation and is based mainly on empirical experience and inference from in vitro findings on a trial-and-error basis. As recently concluded, there is no conclusive evidence to support any specific approach.<sup>56</sup> Such conclusions are in substantial agreement with others<sup>6,15,83</sup> and stress, once more, the need for well-designed clinical trials and experimentally controlled investigations. Because of the relatively rare occurrence of failing implants, international multicenter cooperation, based on strict adherence to well-defined therapeutic approaches, is needed for achieving significant results.

### Acknowledgments

Financial support from the National Research Council of Italy (CNR), the Swedish Medical Research Council (9495), Nutek, Göteborg Medical Society, the Faculties of Odontology and Medicine at Göteborg University, the C. M. Leric Foundation, the Hjalmar Svensson Foundation, the Greta and Einar Asker Foundation, and the Adlerbertska Research Fund is gratefully acknowledged. No financial support has been received from any oral implant company.

### References

1. Esposito M, Hirsch J-M, Lekholm U, Thomsen P. Biological factors contributing to failures of osseointegrated oral implants. (I) Success criteria and epidemiology. *Eur J Oral Sci* 1998;106:527-551.
2. Esposito M, Hirsch J-M, Lekholm U, Thomsen P. Biological factors contributing to failures of osseointegrated oral implants. (II) Etiopathogenesis. *Eur J Oral Sci* 1998;106:721-764.
3. Keller EE. Placement of dental implants in the irradiated mandible: A protocol without adjunctive hyperbaric oxygen. *J Oral Maxillofac Surg* 1997;55:972-980.
4. Orton GO, Steele DL, Wolinsky LE. The dental professional's role in monitoring and maintenance of tissue-integrated prostheses. *Int J Oral Maxillofac Implants* 1989;4:305-310.
5. Jensen RL, Jensen JH. Peri-implant maintenance. *Northwest Dent* 1991;70:14-30.
6. Bragger U. Maintenance, monitoring, therapy of implant failures. In: Lang NP, Karring T (eds). *Proceedings of the 1st European Workshop on Periodontology*. London: Quintessence, 1994:345-364.
7. Von Arx T, Kurt B, Hardt N. Treatment of severe peri-implant bone loss using autogenous bone and a resorbable membrane. Case report and literature review. *Clin Oral Implants Res* 1997;8:517-526.
8. Mombelli A, Lang NP. The diagnosis and treatment of peri-implantitis. *Periodontol* 2000 1998;17:63-76.
9. Duyck J, Naert I. Failure of oral implants: Aetiology, symptoms and influencing factors. *Clin Oral Investig* 1998;2:102-114.
10. Tonetti MS. Risk factors for osseodisintegration. *Periodontol* 2000 1998;17:55-62.
11. Newman MG. Improved clinical decision making using the evidence-based approach. *Ann Periodontol* 1996;1:i-ix.
12. Sox HCJ, Blatt M, Higgins MC, Marton KI. *Medical Decision Making*. Boston: Butterworth-Heinemann, 1988.
13. Anderson DM, Keith J, Novak PD, Elliott MA (eds). *Dorland's Illustrated Medical Dictionary*, ed 28. Philadelphia: WB Saunders, 1994:1198.
14. Isidor F. Mobility assessment with the Periotest system in relation to histologic findings of oral implants. *Int J Oral Maxillofac Implants* 1998;13:377-383.
15. Albrektsson T, Isidor F. Consensus report of session IV. In: Lang NP, Karring T (eds). *Proceedings of the 1st European Workshop on Periodontology*. London: Quintessence, 1994:365-369.
16. Krauser JT. Hydroxylapatite-coated dental implants. Biologic rationale and surgical technique. *Dent Clin North Am* 1989;33:879-903.
17. Kwan JY, Zablotsky MH. The ailing implant. *J Calif Dent Assoc* 1991;19:51-56.
18. Golec TS, Krauser JT. Long-term retrospective studies on hydroxyapatite-coated endosteal and subperiosteal implants. *Dent Clin North Am* 1992;36:39-65.
19. Meffert RM. How to treat ailing and failing implants. *Implant Dent* 1992;1:25-33.
20. Tarnow DP. Dental implants in periodontal care. *Curr Opin Periodontol* 1993;157-162.
21. Zablotsky M, Kwan J. Peri-implantitis: Etiology of the ailing, failing, or failed dental implant. In: Hall WB, Roberts WE, LaBarre EE (eds). *Decision Making in Dental Treatment Planning*. St. Louis: Mosby, 1994:84-85.
22. Torosian J, Rosenberg ES. The failing and the failed implant: A clinical, microbiologic, and treatment review. *J Esthet Dent* 1993;5:97-100.
23. Mombelli A, van Oosten MAC, Schürch EJ, Lang NP. The microbiota associated with successful or failing osseointegrated titanium implants. *Oral Microbiol Immunol* 1987;2:145-151.
24. Sanz M, Alandez J, Lazzaro P, Calvo JL, Quirynen M, van Steenberghe D. Histo-pathologic characteristics of peri-implant soft tissues in Brånemark implants with 2 distinct clinical and radiological patterns. A histometric and ultrastructural study. *Clin Oral Implants Res* 1991;2:128-134.
25. Rosenberg ES, Torosian JP, Slots J. Microbial differences in 2 clinically distinct types of failures of osseointegrated implants. *Clin Oral Implants Res* 1991;2:135-144.
26. Tonetti MS, Schmid J. Pathogenesis of implant failures. *Periodontol* 2000 1994;4:127-138.
27. Isidor F. Loss of osseointegration caused by occlusal load of oral implants. A clinical and radiographic study in monkeys. *Clin Oral Implants Res* 1996;7:143-152.

28. Isidor F. Histological evaluation of peri-implant bone at implants subjected to occlusal overload or plaque accumulation. *Clin Oral Implants Res* 1997;8:1-9.
29. Esposito M, Thomsen P, Mölne J, Gretzer C, Ericson LE, Lekholm U. Immunohistochemistry of soft tissues surrounding late failures of Brånemark implants. *Clin Oral Implants Res* 1997;8:352-366.
30. Esposito M, Lausmaa J, Hirsch J-M, Thomsen P. Surface analysis of failed titanium oral implants. *J Biomed Mater Res Appl Biomater* 1999;48:559-568.
31. Petty W, Spanier S, Shuster JJ, Silverthorne C. The influence of skeletal implants on incidence of infection. *J Bone Joint Surg [Am]* 1985;67:1236-1244.
32. Cordero J, Munuera L, Folgueira MD. Influence of metal implants on infection. An experimental study in rabbits. *J Bone Joint Surg [Br]* 1994;76:717-720.
33. Melcher GA, Hauke C, Metzendorf A, Perren G, Schlegel U, Ziegler WJ. Infection after intramedullary nailing: An experimental investigation on rabbits. *Injury* 1996;27 (suppl 3):23-26.
34. Sussman HI, Moss SS. Localized osteomyelitis secondary to endodontic-implant pathosis. A case report. *J Periodontol* 1993;64:306-310.
35. Tonetti MS. Peri-implantitis: Biological considerations. *J Parodontol Implantol Oral* 1996;15:269-284.
36. Schou S, Holmstrup P, Hjørtting-Hansen E, Lang NP. Plaque-induced marginal tissue reactions of osseointegrated oral implants: A review of the literature. *Clin Oral Implants Res* 1992;3:149-161.
37. Pontoriero R, Tonelli MP, Carnevale G, Mombelli A, Nyman SR, Lang NP. Experimentally induced peri-implant mucositis. *Clin Oral Implants Res* 1994;5:254-259.
38. Quirynen M, van Steenberghe D. Bacterial colonization of the internal part of two-stage implants. An in vivo study. *Clin Oral Implants Res* 1993;4:158-161.
39. Persson LG, Lekholm U, Leonhardt Å, Dahlén G, Lindhe J. Bacterial colonization on internal surfaces of Brånemark system implant components. *Clin Oral Implants Res* 1996;7:90-95.
40. Worthington P, Bolender CL, Taylor TD. The Swedish system of osseointegrated implants: Problems and complications encountered during a 4-year trial period. *Int J Oral Maxillofac Implants* 1987;2:77-84.
41. Sones AD. Complications with osseointegrated implants. *J Prosthet Dent* 1989;62:581-585.
42. Zarb GA, Schmitt A. The longitudinal clinical effectiveness of osseointegrated dental implants: The Toronto study. Part III: Problems and complications encountered. *J Prosthet Dent* 1990;64:185-194.
43. Jemt T. Failures and complications in 391 consecutively inserted fixed prostheses supported by Brånemark implants in edentulous jaws: A study of treatment from the time of prosthesis placement to the first annual checkup. *Int J Oral Maxillofac Implants* 1991;6:270-276.
44. Henry PJ. Maintenance and monitoring. In: Worthington P, Brånemark P-I (eds). *Advanced Osseointegration Surgery: Applications in the Maxillofacial Region*. Chicago: Quintessence, 1992:356-367.
45. Jemt T, Pettersson P. A 3-year follow-up study on single implant treatment. *J Dent* 1993;21:203-208.
46. Cordioli G, Castagna S, Consolati E. Single-tooth implant rehabilitation: A retrospective study of 67 implants. *Int J Prosthodont* 1994;7:525-531.
47. Ekfeldt A, Carlsson GE, Börjesson G. Clinical evaluation of single-tooth restorations supported by osseointegrated implants: A retrospective study. *Int J Oral Maxillofac Implants* 1994;9:179-183.
48. Öhrnell L-O, Palmquist J, Brånemark P-I. Single tooth replacement. In: Worthington P, Brånemark P-I (eds). *Advanced Osseointegration Surgery: Applications in the Maxillofacial Region*. Chicago: Quintessence, 1992: 211-232.
49. Ibbott CG, Kovach RJ, Carlson-Mann LD. Acute periodontal abscess associated with an immediate implant site in the maintenance phase: A case report. *Int J Oral Maxillofac Implants* 1993;8:699-702.
50. Engquist B, Bergendal T, Kallus T, Linden U. A retrospective multicenter evaluation of osseointegrated implants supporting overdentures. *Int J Oral Maxillofac Implants* 1988;3:129-134.
51. Jemt T, Book K, Lindén B, Urde G. Failures and complications in 92 consecutively inserted overdentures supported by Brånemark implants in severely resorbed edentulous maxillae: A study from prosthetic treatment to first annual check-up. *Int J Oral Maxillofac Implants* 1992;7:162-167.
53. Smedberg J-I, Svensäter G, Edwardsson S. The microflora adjacent to osseointegrated implants supporting maxillary removable prostheses. *Clin Oral Implants Res* 1993;4: 165-171.
53. Chee WWL, Jansen CE. Phenytoin hyperplasia occurring in relation to titanium implants: A clinical report. *Int J Oral Maxillofac Implants* 1994;9:107-109.
54. Jovanovic SA. Diagnosis and treatment of peri-implant disease. *Curr Opin Periodontol* 1994;194-204.
55. Cochran D. Implant therapy I. *Ann Periodont* 1996; 1:707-790.
56. Nevins M, Meffert R, Tarnow D, Cochran D, Cohen R, Iacono V, et al (eds). Consensus report. Implant therapy I. Proceedings of the 1996 World Workshop in Periodontics. *Ann Periodontol* 1996;1:792-795.
57. Lekholm U, Adell R, Brånemark P-I. Complications. In: Brånemark P-I, Zarb GA, Albrektsson T (eds). *Tissue-Integrated Prostheses*. Chicago: Quintessence, 1985:233-240.
58. Worthington P. Problems and complications with osseointegrated implants. In: Worthington P, Brånemark P-I (eds). *Advanced Osseointegration Surgery: Applications in the Maxillofacial Region*. Chicago: Quintessence, 1992: 386-396.
59. Listgarten MA. Clinical trials of endosseous implants: Issues in analysis and interpretation. *Ann Periodontol* 1997;2:299-313.
60. Listgarten MA. Soft and hard tissue response to endosseous dental implants. *Anat Rec* 1996;245:410-425.
61. McAllister BS, Masters D, Meffert RM. Treatment of implants demonstrating periapical radiolucencies. *Pract Periodontics Aesthet Dent* 1992;4:37-41.
62. Balshi TJ, Pappas CE, Wolfinger GJ, Hernandez RE. Management of an abscess around the apex of a mandibular root-form implant: Clinical report. *Implant Dent* 1994;3:81-85.
63. Reiser GM, Nevins M. The implant periapical lesion: Etiology, prevention, and treatment. *Compend Contin Educ Dent* 1995;16:768-777.
64. Piattelli A, Scarano A, Piattelli M. Abscess formation around the apex of a maxillary root form implant: Clinical and microscopical aspects. A case report. *J Periodontol* 1995;66:899-903.

65. Piattelli A, Scarano A, Piattelli M, Podda G. Implant peri-apical lesions: Clinical, histologic, and histochemical aspects. A case report. *Int J Periodontics Restorative Dent* 1998;18:181-187.
66. Piattelli A, Scarano A, Balleri P, Favero GA. Clinical and histological evaluation of an active "implant periapical lesion": A case report. *Int J Oral Maxillofac Implants* 1998;13:713-716.
67. Mombelli A, Lang NP. Antimicrobial treatment of peri-implant infections. *Clin Oral Implants Res* 1992;3:162-168.
68. Lekholm U, Sennerby L, Roos J, Becker W. Soft tissue and marginal bone conditions at osseointegrated implants that have exposed threads: A 5-year retrospective study. *Int J Oral Maxillofac Implants* 1996;11:599-604.
69. Lozada JL, James RA, Boskovic M, Cordova C, Emanuelli S. Surgical repair of peri-implant defects. *J Oral Implantol* 1990;16:42-46.
70. Jovanovic SA, Spiekermann H, Richter E-J, Koseoglu M. Guided tissue regeneration around titanium dental implants. In: Laney WR, Tolman DE (eds). *Tissue Integration in Oral, Orthopedic, and Maxillofacial Reconstruction*. Proceedings of the Second International Congress on Tissue Integration in Oral, Orthopedic, and Maxillofacial Reconstruction. Chicago: Quintessence, 1992:208-215.
71. Mellonig JT, Triplett RG. Guided tissue regeneration and endosseous dental implants. *Int J Periodontics Restorative Dent* 1993;13:109-119.
72. Newman MG, Flemmig TF. Bacteria-host interactions. In: Worthington P, Brånemark P-I (eds). *Advanced Osseointegration Surgery: Applications in the Maxillofacial Region*. Chicago: Quintessence, 1992:67-79.
73. Flemmig TF, Newman MG. Antimicrobials in implant dentistry. In: Newman MG, Kornman K (eds). *Antibiotics/Antimicrobial Use in Dental Practice*. Chicago: Quintessence, 1990:187-200.
74. Zablotsky M. The surgical management of osseous defects associated with endosteal hydroxyapatite-coated and titanium dental implants. *Dent Clin North Am* 1992;36:117-149.
75. Jovanovic SA. The management of peri-implant breakdown around functioning osseointegrated dental implants. *J Periodontol* 1993;64:1176-1183.
76. Zablotsky MH. Chemotherapeutics in implant dentistry. *Implant Dent* 1993;2:19-25.
77. Zablotsky M, Kwan J. Initial therapy for the ailing/failing dental implant. In: Hall WB, Roberts WE, LaBarre EE (eds). *Decision Making in Dental Treatment Planning*. St. Louis: Mosby, 1994:86-87.
78. Zablotsky M, Kwan J. The surgical management of peri-implantitis: Implant repair. In: Hall WB, Roberts WE, LaBarre EE (eds). *Decision Making in Dental Treatment Planning*. St. Louis: Mosby, 1994:88-91.
79. Danesh-Meyer MJ. Dental implants. Part II: Guided bone regeneration, immediate implant placement, peri-implantitis, failing implants. *J N Z Soc Periodontol* 1994;78:18-28.
80. Meffert RM. Periodontitis vs. peri-implantitis: The same disease? The same treatment? *Crit Rev Oral Biol Med* 1996;7:278-291.
81. Bower RC. Peri-implantitis. *Ann R Australas Coll Dent Surg* 1996;13:48-57.
82. Buser D, Maeglin B. Complications with ITI implants. In: Schroeder A, Sutter F, Buser D, Krekeler G (eds). *Oral Implantology. Basics, ITI Hollow-Cylinder System*. Stuttgart: Thieme, 1996:445-476.
83. Lang NP, Mombelli A, Tonetti MS, Brägger U, Hämmerle CHF. Clinical trials on therapies for peri-implant infections. *Ann Periodontol* 1997;2:343-356.
84. Kao RT, Curtis DA, Murray PA. Diagnosis and management of peri-implant disease. *J Calif Dent Assoc* 1997;25:872-880.
85. Mombelli A. Etiology, diagnosis, and treatment considerations in peri-implantitis. *Curr Opin Periodontol* 1997;4:127-136.
86. Dent CD, Olson JW, Farish SE, Bellome J, Casino AJ, Morris HF, Ochi S. The influence of preoperative antibiotics on success of endosseous implants up to and including stage II surgery: A study of 2,641 implants. *J Oral Maxillofac Surg* 1997;55(suppl 5):19-24.
87. Gynther GW, Köndell PÅ, Moberg L-E, Heimdahl A. Dental implant installation without antibiotic prophylaxis. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 1998;85:509-511.
88. Lambert PM, Morris HF, Ochi S. The influence of 0.12% chlorhexidine digluconate rinses on the incidence of infectious complications and implant success. *J Oral Maxillofac Surg* 1997;55(suppl 5):25-30.
89. Ciancio SG, Lauciello F, Shibly O, Vitello M, Mather M. The effect of an antiseptic mouthrinse on implant maintenance: Plaque and peri-implant gingival tissues. *J Periodontol* 1995;66:962-965.
90. Felo A, Shibly O, Ciancio SG, Lauciello FR, Ho A. Effects of subgingival chlorhexidine irrigation on peri-implant maintenance. *Am J Dent* 1997;10:107-110.
91. Lavigne SE, Krust-Bray KS, Williams KB, Killoy WJ, Theisen F. Effects of subgingival irrigation with chlorhexidine on the periodontal status of patients with HA-coated integral dental implants. *Int J Oral Maxillofac Implants* 1994;9:156-162.
92. Strooker H, Rohn S, Van Winkelhoff AJ. Clinical and microbiologic effects of chemical versus mechanical cleansing in professional supportive implant therapy. *Int J Oral Maxillofac Implants* 1998;13:845-850.
93. Jeffcoat MK, Reddy MS, Wang IC, Meuninghoff LA, Farmer JB, Koth DL. The effect of systemic flurbiprofen on bone supporting dental implants. *J Am Dent Assoc* 1995;126:305-311.
94. Lekholm U, Ericsson I, Adell R, Slots J. The condition of the soft tissues at tooth and fixture abutments supporting fixed bridges. A microbiological and histological study. *J Clin Periodontol* 1986;13:560-562.
95. Apse P, Ellen RP, Overall CM, Zarb GA. Microbiota and crevicular fluid collagenase activity in the osseointegrated dental implant sulcus: A comparison of sites in edentulous and partially edentulous patients. *J Periodont Res* 1989;24:96-105.
96. Quirynen M, Listgarten MA. The distribution of bacterial morphotypes around natural teeth and titanium implants ad modum Brånemark. *Clin Oral Implants Res* 1990;1:8-12.
97. Mombelli A, Marxer M, Gaberthüel T, Grunder U, Lang NP. The microbiota of osseointegrated implants in patients with a history of periodontal disease. *J Clin Periodontol* 1995;22:124-130.
98. Papaioannou W, Quirynen M, van Steenberghe D. The influence of periodontitis on the subgingival flora around implants in partially edentulous patients. *Clin Oral Implants Res* 1996;7:405-409.

99. Meffert RM, Singleton DG. Reactors' summary. Clinical trials on endosseous implants, part I. *Ann Periodontol* 1997;2:314.
100. Adell R, Lekholm U, Brånemark P-I. Surgical procedures. In: Brånemark P-I, Zarb GA, Albrektsson T (eds). *Tissue-Integrated Prostheses*. Chicago: Quintessence, 1985: 211-232.
101. Papaioannou W, Quirynen M, Nys M, van Steenberghe D. The effect of periodontal parameters on the subgingival microbiota around implants. *Clin Oral Implants Res* 1995;6:197-204.
102. Schroeder A, van der Zypen E, Stich H, Sutter F. The reactions of bone, connective tissue, and epithelium to endosteal implants with titanium-sprayed surfaces. *J Maxillofac Surg* 1981;9:15-25.
103. Adell R, Lekholm U, Rockler B, Brånemark P-I. A 15-year study of osseointegrated implants in the treatment of the edentulous jaw. *Int J Oral Surg* 1981;10:387-416.
104. Köndell PÅ, Landt H, Nordenram Å, Carlsson B, Danielsson K. The tissue-integrated prosthesis in the treatment of edentulous patients. *Swed Dent J* 1988; 12:11-16.
105. Horning GM, Mullen MP. Peri-implant free gingival grafts: Rationale and technique. *Compend Contin Educ Dent* 1990;11:604-609.
106. Ten Bruggenkate CM, Krekeler G, van der Kwast WAM, Oosterbeek HS. Palatal mucosa grafts for oral implant devices. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 1991;72:154-158.
107. Buser D. Mucogingival surgery. In: Schroeder A, Sutter F, Krekeler G (eds). *Basics—ITI Hollow Cylinder*. Stuttgart: Thieme, 1991:295-307.
108. Maeglin B. Difficulties and complications. In: Schroeder A, Sutter F, Krekeler G (eds). *Basics—ITI Hollow Cylinder*. Stuttgart: Thieme, 1991:331-343.
109. Artzi Z, Tal H, Moses O, Kozlovsky A. Mucosal considerations for osseointegrated implants. *J Prosthet Dent* 1993;70:427-432.
110. Simons AM, Garany DG, Giordano JR. The use of free gingival grafts in the treatment of peri-implant soft tissue complications: Clinical report. *Implant Dent* 1993;2: 27-30.
111. Artzi Z, Tal H, Chweidan H. Bone regeneration for reintegration in peri-implant destruction. *Compend Contin Educ Dent* 1998;19:17-30.
112. Meffert RM, Langer B, Fritz ME. Dental implants: A review. *J Periodontol* 1992;63:859-870.
113. Salonen MAM, Oikarinen K, Virtanen K, Pernu H. Failures in the osseointegration of endosseous implants. *Int J Oral Maxillofac Implants* 1993;8:92-97.
114. Kirsch A, Ackermann KL. The IMZ osteointegrated implant system. *Dent Clin North Am* 1989;33:733-791.
115. Block MS, Kent JN. Factors associated with soft- and hard-tissue compromise of endosseous implants. *J Oral Maxillofac Surg* 1990;48:1153-1160.
116. Hertel RC, Blijdorp PA, Baker DL. A preventive mucosal flap technique for use in implantology. *Int J Oral Maxillofac Implants* 1993;8:452-458.
117. Block MS, Gardiner D, Kent JN, Misiek DJ, Finger IM, Guerra L. Hydroxyapatite-coated cylindrical implants in the posterior mandible: 10-year observations. *Int J Oral Maxillofac Implants* 1996;11:626-633.
118. Krekeler G, Schilli W, Diemer J. Should the exit of the artificial abutment tooth be positioned in the region of the attached gingiva? *Int J Oral Surg* 1985;14:504-508.
119. Adell R, Lekholm U, Rockler B, Brånemark P-I, Lindhe J, Eriksson B, Sbordone L. Marginal tissue reactions at osseointegrated titanium fixtures (I). A 3-year longitudinal prospective study. *Int J Oral Maxillofac Implants* 1986;15:39-52.
120. Lekholm U, Adell R, Lindhe J, Brånemark P-I, Eriksson B, Rockler B, et al. Marginal tissue reactions at osseointegrated titanium fixtures. (II). A cross-sectional retrospective study. *Int J Oral Maxillofac Surg* 1986;15:53-61.
121. Cox JF, Zarb GA. The longitudinal clinical efficacy of osseointegrated dental implants: A 3-year report. *Int J Oral Maxillofac Implants* 1987;2:91-100.
122. Strub JR, Gaberthüel TW, Grunder U. The role of attached gingiva in the health of peri-implant tissue in dogs. Part I. Clinical findings. *Int J Periodontics Restorative Dent* 1991;11:317-333.
123. Apse P, Zarb GA, Schmitt A, Lewis DW. The longitudinal effectiveness of osseointegrated dental implants. The Toronto study: Peri-implant mucosal response. *Int J Periodontics Restorative Dent* 1991;11:95-111.
124. Mericske-Stern R, Zarb GA. Overdentures: An alternative implant methodology for edentulous patients. *Int J Prosthodont* 1993;6:203-208.
125. Wennström JL, Bengazi F, Lekholm U. The influence of the masticatory mucosa on the peri-implant soft tissue condition. *Clin Oral Implants Res* 1994;5:1-8.
126. Warrer K, Buser D, Lang NP, Karring T. Plaque-induced peri-implantitis in the presence or absence of keratinized mucosa. *Clin Oral Implants Res* 1995;6:131-138.
127. Bengazi F, Wennström JL, Lekholm U. Recession of the soft tissue margin at oral implants. A 2-year longitudinal prospective study. *Clin Oral Implants Res* 1996;7: 303-310.
128. Nevins M, Kenney E, van Steenberghe D, Fritz M, Beecker W, Ferris G, et al (eds). Consensus report. Implant therapy II. Proceedings of the 1996 World Workshop in Periodontics. *Ann Periodontol* 1996;1:816-820.
129. Brägger U, Bürgin WB, Hämmerle CHF, Lang NP. Associations between clinical parameters assessed around implants and teeth. *Clin Oral Implants Res* 1997;8: 412-421.
130. Kraut RA, Kuhar KJ, Shernoff AF. Hydroxyapatite-coated dental implants used for the treatment of edentulous mandibles. *Compend Contin Educ Dent* 1988;9:402-409.
131. Gregory M, Murphy WM, Scott J, Watson CJ, Reeve PE. A clinical study of the Brånemark dental implant system. *Br Dent J* 1990;168:18-23.
132. Quirynen M. Tissue response to loading and microbiota. In: Naert I, van Steenberghe D, Worthington P (eds). *Osseointegration in Oral Rehabilitation*. London: Quintessence, 1993:171-180.
133. Kenney EB, Jovanovic SA. Osteopromotion as an adjunct to osseointegration. *Int J Prosthodont* 1993;6:131-136.
134. Thomson-Neal D, Evans GH, Meffert RM. Effects of various prophylactic treatments on titanium, sapphire, and hydroxyapatite-coated implants: An SEM study. *Int J Periodontics Restorative Dent* 1989;9:301-311.
135. Rapley JW, Swan RH, Hallmon WW, Mills MP. The surface characteristics produced by various oral hygiene instruments and materials on titanium implant abutments. *Int J Oral Maxillofac Implants* 1990;5:47-52.
136. Fox SC, Moriarty JD, Kusy RP. The effects of scaling a titanium implant surface with metal and plastic instruments: An in vitro study. *J Periodontol* 1990;61:485-490.

137. Dmytryk JJ, Fox SC, Moriarty JD. The effects of scaling titanium implant surfaces with metal and plastic instruments on cell attachment. *J Periodontol* 1990;61:491-496.
138. Gantes BG, Nilveus R. The effects of different hygiene instruments on titanium surfaces: SEM observations. *Int J Periodontics Restorative Dent* 1991;11:225-239.
139. Homiak AW, Cook PA, DeBoer J. Effect of hygiene instrumentation on titanium abutments: A scanning electron microscopy study. *J Prosthet Dent* 1992;67:364-369.
140. Rühling A, Kocher T, Kreuzsch J, Plagmann H-C. Treatment of subgingival implant surfaces with Teflon-coated sonic and ultrasonic scaler tips and various implant curettes. An in vitro study. *Clin Oral Implants Res* 1994;5:19-29.
141. Kuempel DR, Johnson GK, Zaharias RS, Keller JC. The effects of scaling procedures on epithelial cell growth on titanium surfaces. *J Periodontol* 1995;66:228-234.
142. Hallmon WW, Waldrop TC, Meffert RM, Wade BW. A comparative study of the effects of metallic, nonmetallic, and sonic instrumentation on titanium abutment surfaces. *Int J Oral Maxillofac Implants* 1996;11:96-100.
143. Matarasso S, Quaremba G, Coraggio F, Vaia E, Cafiero C, Lang NP. Maintenance of implants: An in vitro study of titanium implant surface modifications subsequent to the application of different prophylaxis procedures. *Clin Oral Implants Res* 1996;7:64-72.
144. Meschenmoser A, d'Hoedt B, Meyle J, Elssner G, Korn D, Hämmerle H, Schulte W. Effects of various hygiene procedures on the surface characteristics of titanium abutments. *J Periodontol* 1996;67:229-235.
145. Brookshire FVG, Nagy WW, Dhuru VB, Ziebert GJ, Chada S. The qualitative effects of various types of hygiene instrumentation on commercially pure titanium and titanium alloy implant abutments: An in vitro and scanning electron microscope study. *J Prosthet Dent* 1997;78:286-294.
146. Cross-Poline G, Shaklee RL, Stach DJ. Effect of implant curets on titanium implant surfaces. *Am J Dent* 1997;10:41-45.
147. Mengel R, Buns C-E, Mengel C, Flores-de-Jacoby L. An in vitro study of the treatment of implant surfaces with different instruments. *Int J Oral Maxillofac Implants* 1998;13:91-96.
148. Siirilä HS, Könönen M. The effect of oral topical fluorides on the surface of commercially pure titanium. *Int J Oral Maxillofac Implants* 1991;6:50-54.
149. Speelman JA, Collaert B, Klinge B. Evaluation of different methods to clean titanium abutments. *Clin Oral Implants Res* 1992;3:120-127.
150. Krekeler G. Follow-up care and recall. In: Schroeder A, Sutter F, Buser D, Krekeler G (eds). *Oral Implantology. Basics, ITI Hollow Cylinder System*. Stuttgart: Thieme, 1996:420-427.
151. Burchard WB, Cobb CM, Drisko CL, Killoy WJ. The effects of chlorhexidine and stannous fluoride on fibroblast attachment to different implant surfaces. *Int J Oral Maxillofac Implants* 1991;6:418-426.
152. Schenk G, Flemmig TF, Betz T, Reuther J, Klaiber B. Controlled local delivery of tetracycline HCl in the treatment of periimplant mucosal hyperplasia and mucositis. A controlled case series. *Clin Oral Implants Res* 1997;8:427-433.
153. Haanaes HR. Implants and infections with special reference to oral bacteria. *J Clin Periodontol* 1990;17:516-524.
154. Sbordone L, Barone A, Ramaglia L, Ciaglia RN, Iacono VJ. Antimicrobial susceptibility of periodontopathic bacteria associated with failing implants. *J Periodontol* 1995;66:69-74.
155. Costerton JW, Irvin RT, Cheng K-J. The bacterial glycocalyx in nature and disease. *Annu Rev Microbiol* 1981;35:299-324.
156. Costerton JW. The etiology and persistence of cryptic bacterial infections: A hypothesis. *Rev Infect Dis* 1984;6(suppl 3):608-616.
157. Gristina AG, Oga M, Webb LX, Hobgood CD. Adherent bacterial colonization in the pathogenesis of osteomyelitis. *Science* 1985;228:990-993.
158. Gristina AG. Biomaterial-centered infection: Microbial adhesion versus tissue integration. *Science* 1987;237:1588-1595.
159. Nishioka GJ, Jones J, Triplett RG, Aufdemorte TB. The role of bacteria-laden biofilms in infections of maxillofacial biomaterials. *J Oral Maxillofac Surg* 1988;46:19-25.
160. Gristina AG, Hobgood CD, Webb LX, Myrvik QN. Adhesive colonization of biomaterials and antibiotic resistance. *Biomaterials* 1987;8:423-426.
161. Gristina AG, Jennings RA, Naylor PT, Myrvik QN, Webb LX. Comparative in vitro antibiotic resistance of surface-colonizing coagulase-negative *Staphylococci*. *Antimicrob Agents Chemother* 1989;33:813-816.
162. Widmer AF, Frei R, Rajacic Z, Zimmerli W. Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections. *J Infect Dis* 1990;162:96-102.
163. Khoury AE, Lam K, Ellis B, Costerton W. Prevention and control of bacterial infections associated with medical devices. *ASAIO J* 1992;38:M174-M178.
164. Van Winkelhoff AJ, Rodenburg JP, Groené RJ, Abbas F, Winkel EG, de Graaff J. Metronidazole plus amoxicillin in the treatment of *Actinobacillus actinomycetemcomitans* associated periodontitis. *J Clin Periodontol* 1989;16:128-131.
165. Ericsson I, Persson LG, Berglundh T, Edlund T, Lindhe J. The effect of antimicrobial therapy on peri-implantitis lesions. An experimental study in the dog. *Clin Oral Implants Res* 1996;7:320-328.
166. Weber HP, Fiorellini JP, Paquette DW, Howell TH, Williams RC. Inhibition of peri-implant bone loss with the nonsteroidal anti-inflammatory drug flurbiprofen in beagle dogs. A preliminary study. *Clin Oral Implants Res* 1994;5:148-153.
167. Mellonig JT, Griffiths G, Mathys E, Spitznagel JJ. Treatment of the failing implant: Case reports. *Int J Periodontics Restorative Dent* 1995;15:385-395.
168. Henry PJ, Bower RC, Wall CD. Rehabilitation of the edentulous mandible with osseointegrated dental implants: 10-year follow-up. *Aust Dent J* 1995;40:1-9.
169. Zarb GA, Schmitt A. The edentulous predicament I: A prospective study of the effectiveness of implant-supported fixed prostheses. *J Am Dent Assoc* 1996;127:59-65.
170. Quirynen M, Naert I, van Steenberghe D, Dekeyser C, Callens A. Periodontal aspects of osseointegrated fixtures supporting a partial bridge. An up to 6-years retrospective study. *J Clin Periodontol* 1992;19:118-126.



171. Tolman DE, Laney WR. Tissue-integrated prosthesis complications. *Int J Oral Maxillofac Implants* 1992;7:477-484.
172. Dennison DK, Huerzeler MB, Quinones C, Caffesse RG. Contaminated implant surfaces: An in vitro comparison of implant surface coating and treatment modalities for decontamination. *J Periodontol* 1994;65:942-948.
173. Parham PLJ, Cobb CM, French AA, Love JW, Drisko CL, Killoy WJ. Effects of an air-powder abrasive system on plasma-sprayed titanium implant surfaces: An in vitro evaluation. *J Oral Implantol* 1989;15:78-86.
174. O'Neal RB, Sauk JJ, Somerman MJ. Biological requirements for material integration. *J Oral Implantol* 1992;18:243-255.
175. Wittrig EE, Zablotsky MH, Layman DL, Meffert RM. Fibroblastic growth and attachment on hydroxyapatite-coated titanium surfaces following the use of various detoxification modalities. Part I: Noncontaminated hydroxyapatite. *Implant Dent* 1992;1:189-194.
176. Zablotsky MH, Wittrig EE, Diedrich DL, Layman DL, Meffert RM. Fibroblastic growth and attachment on hydroxyapatite-coated titanium surfaces following the use of various detoxification modalities. Part II: Contaminated hydroxyapatite. *Implant Dent* 1992;1:195-202.
177. Lehmann B, Brägger U, Hämmerle CHF, Fourmouis I, Lang NP. Treatment of an early implant failure according to the principles of guided tissue regeneration (GTR). *Clin Oral Implants Res* 1992;3:42-48.
178. Hämmerle CHF, Fourmouis I, Winkler JR, Weigel C, Brägger U, Lang NP. Successful bone fill in later peri-implant defects using guided tissue regeneration. A short communication. *J Periodontol* 1995;66:303-308.
179. Zablotsky M, Diedrich D, Meffert R, Wittrig E. The ability of various chemotherapeutic agents to detoxify the endotoxin infected HA-coated implant surface. *Int J Oral Implantol* 1991;8:45-51.
180. Zablotsky MH, Diedrich DL, Meffert RM. Detoxification of endotoxin-contaminated titanium and hydroxyapatite-coated surfaces utilizing various chemotherapeutic and mechanical modalities. *Implant Dent* 1992;1:154-158.
181. Bell FA, Cavazos EJJ, Jones AA, Stewart KL. Four-year experience with the placement, restoration, and maintenance of dental implants by dental students. *Int J Oral Maxillofac Implants* 1994;9:725-731.
182. Zablotsky M, Meffert R, Mills O, Burgess A, Lancaster D. The macroscopic, microscopic and spectrometric effects of various chemotherapeutic agents on the plasma-sprayed hydroxyapatite-coated implant surface. *Clin Oral Implants Res* 1992;3:189-198.
183. Mouhyi J, Sennerby L, Pireaux J-J, Dourov N, Nammour S, Van Reck J. An XPS and SEM evaluation of six chemical and physical techniques for cleaning of contaminated titanium implants. *Clin Oral Implants Res* 1998;9:185-194.
184. Bergendal T, Forsgren L, Kvint S, Löwstedt E. The effect of an airbrasive instrument on soft and hard tissues around osseointegrated implants. A case report. *Swed Dent J* 1990;14:219-223.
185. Brown FH, Ogletree RC, Houston GD. Pneumoparotitis associated with the use of an air-powder prophylaxis unit. *J Periodontol* 1992;63:642-644.
186. Messier DY. Coroner's report: Circumstances of a death related to implant surgery procedures. *Int J Oral Implantol* 1989;6:50-63.
187. Davies JM, Campbell LA. Fatal air embolism during dental implant surgery: A report of three cases. *Can J Anaesth* 1990;37:112-121.
188. Haas R, Dörthbudak O, Mensdorff-Pouilly N, Mailath G. Elimination of bacteria on different implant surfaces through photosensitization and soft laser. An in vitro study. *Clin Oral Implants Res* 1997;8:249-254.
189. Oyster DK, Parker WB, Gher ME. CO<sub>2</sub> lasers and temperature changes of titanium implants. *J Periodontol* 1995;66:1017-1024.
190. Eriksson AR, Albrektsson T. Temperature threshold levels for heat-induced bone tissue injury: A vital-microscopic study in the rabbit. *J Prosthet Dent* 1983;50:101-107.
191. Ganz CH. Evaluation of the safety of the carbon dioxide laser used in conjunction with root-form implants: A pilot study. *J Prosthet Dent* 1994;71:27-30.
192. Block CM, Mayo JA, Evans GH. Effects of the Nd:YAG dental laser on plasma-sprayed and hydroxyapatite-coated titanium dental implants: Surface alteration and attempted sterilization. *Int J Oral Maxillofac Implants* 1992;7:441-449.
193. Walsh LJ. The use of laser in implantology: An overview. *J Oral Implantol* 1992;18:335-340.
194. Åstrand P, Almfeldt I, Brunell G, Hamp S-E, Hellem S, Karlsson U. Non-submerged implants in the treatment of the edentulous lower jaw. A 2-year longitudinal study. *Clin Oral Implants Res* 1996;7:337-344.
195. Hermann JS, Buser D. Guided bone regeneration for dental implants. *Curr Opin Periodontol* 1996;3:168-177.
196. Goldman MJ. Bone regeneration around a failing implant using guided tissue regeneration. A case report. *J Periodontol* 1992;63:473-476.
197. Kraut RA, Judy KWM. Implant preservation using guided tissue augmentation membrane and porous hydroxyapatite. *Int J Oral Implantol* 1991;8:55-58.
198. Nowzari H, Slots J. Microbiologic and clinical study of polytetrafluoroethylene membranes for guided bone regeneration around implants. *Int J Oral Maxillofac Implants* 1995;10:67-73.
199. Piattelli A, Scarano A, Dalla Nora A, De Bona G, Favero GA. Microscopical features in retrieved human Brånemark implants: A report of 19 cases. *Biomaterials* 1998;19:643-649.
200. Grunder U, Hürzeler MB, Schüpbach P, Strub JR. Treatment of ligature-induced peri-implantitis using guided tissue regeneration: A clinical and histologic study in the beagle dog. *Int J Oral Maxillofac Implants* 1993;8:282-293.
201. Schüpbach P, Hürzeler M, Grunder U. Implant-tissue interfaces following treatment of peri-implantitis using guided tissue regeneration. A light and electron microscopic study. *Clin Oral Implants Res* 1994;5:55-65.
202. Jovanovic SA, Kenney EB, Carranza FA, Donath K. The regenerative potential of plaque-induced peri-implant bone defects treated by a submerged membrane technique: An experimental study. *Int J Oral Maxillofac Implants* 1993;8:13-18.
203. Singh G, O'Neal RB, Brennan WA, Strong SL, Horner JA, Van Dyke TE. Surgical treatment of induced peri-implantitis in the micro pig: Clinical and histological analysis. *J Periodontol* 1993;64:984-989.
204. Persson LG, Ericsson I, Berglundh T, Lindhe J. Guided bone regeneration in the treatment of peri-implantitis. *Clin Oral Implants Res* 1996;7:366-372.

205. Hürzeler MB, Quiñones CR, Schüpback P, Morrison EC, Caffesse RG. Treatment of peri-implantitis using guided bone regeneration and bone grafts, alone or in combination, in beagle dogs. Part 2: Histologic findings. *Int J Oral Maxillofac Implants* 1997;12:168-175.
206. Hürzeler MB, Quiñones CR, Morrison EC, Caffesse RG. Treatment of peri-implantitis using guided bone regeneration and bone grafts, alone or in combination, in beagle dogs. Part 1: Clinical findings and histologic observations. *Int J Oral Maxillofac Implants* 1995; 10:474-484.
207. Hanisch O, Tatakis DN, Boskovic MM, Rohrer MD, Wikesjö UME. Bone formation and reosseointegration in peri-implantitis defects following surgical implantation of rhBMP-2. *Int J Oral Maxillofac Implants* 1997;12: 604-610.
208. Quirynen M, Bollen CML, Eyssen H, van Steenberghe D. Microbial penetration along the implant components of the Brånemark system. An in vitro study. *Clin Oral Implants Res* 1994;5:239-244.
209. Gammage DD, Bowman AE, Meffert RM. Clinical management of failing dental implants: Four case reports. *J Oral Implantol* 1989;15:124-131.
210. Brånemark P-I, Hansson BO, Adell R, Breine U, Lindström J, Hallén O, Öhman A. *Osseointegrated Implants in the Treatment of the Edentulous Jaw. Experience from a 10-Year Period.* Stockholm: Almqvist & Wiksell International, 1977.
211. Piattelli A, Cosci F, Scarano A, Trisi P. Localized chronic suppurative bone infection as a sequel of peri-implantitis in a hydroxyapatite-coated dental implant. *Biomaterials* 1995;16:917-920.
212. Worthington P. Complications and failures. In: Naert I, van Steenberghe D, Worthington P (eds). *Osseointegration in Oral Rehabilitation.* London: Quintessence, 1993: 181-186.
213. Li KK, Varvares MA, Meara JG. Descending necrotizing mediastinitis: A complication of dental implant surgery. *Head Neck* 1996;18:192-196.
214. Ten Bruggenkate CM, Sutter F, Schroeder A, Oosterbeek HS. Explanation procedure in the F-type and Bonefit ITI implant system. *Int J Oral Maxillofac Surg* 1991;20: 155-158.
215. Ten Bruggenkate CM, Sutter F, van den Berg JPA, Oosterbeek HS. Explanation procedure with special emphasis on the ITI implant system. *Int J Oral Maxillofac Implants* 1994;9:223-229.
216. Hulth A. Current concepts of fracture healing. *Clin Orthop* 1989;249:265-284.
217. Chan MFW-Y, Johnston C, Howell RA, Cawood JI. Prosthetic management of the atrophic mandible using endosseous implants and overdentures: A six year review. *Br Dent J* 1995;179:329-337.
218. Engquist B, Nilson H, Åstrand P. Single-tooth replacement by osseointegrated Brånemark implants. A retrospective study of 82 implants. *Clin Oral Implants Res* 1995;6:238-245.
219. Aspenberg P, Herbertsson P. Periprosthetic bone resorption. *J Bone Joint Surg [Br]* 1996;78:641-646.
220. Ivanoff C-J, Sennerby L, Lekholm U. Reintegration of mobilized titanium implants. An experimental study in rabbit tibia. *Int J Oral Maxillofac Surg* 1997;26:310-315.